Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease.
Saved in:
| Title: | Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease. |
|---|---|
| Authors: | Dowling GA (AUTHOR), Burr RL (AUTHOR), Van Someren EJW (AUTHOR), Hubbard EM (AUTHOR), Luxenberg JS (AUTHOR), Mastick J (AUTHOR), Cooper BA (AUTHOR) |
| Source: | Journal of the American Geriatrics Society. Feb2008, Vol. 56 Issue 2, p239-246. 8p. |
| Abstract: | OBJECTIVES: To test whether the addition of melatonin to bright-light therapy enhances the efficacy in treating rest-activity (circadian) disruption in institutionalized patients with Alzheimer's disease (AD). DESIGN: Randomized, controlled trial. SETTING: Two nursing homes in San Francisco, California. PARTICIPANTS: Fifty subjects (mean age 86) with AD. INTERVENTION: Experimental subjects received 1 hour of morning light exposure (> or = 2,500 lux in gaze direction) Monday to Friday for 10 weeks and 5 mg melatonin (LM, n=16) or placebo (LP, n=17) in the evening. Control subjects (n=17) received usual indoor light (150-200 lux). MEASUREMENTS: Nighttime sleep variables, day sleep time, day activity, day:night sleep ratio, and rest-activity parameters were determined using actigraphy. RESULTS: Linear mixed models were employed to test the primary study hypotheses. No significant differences in nighttime sleep variables were found between groups. At the end of the intervention, the LM group showed significant improvement in daytime somnolence as indicated by a reduction in the duration of daytime sleep, an increase in daytime activity, and an improvement in day:night sleep ratio. The LM group also evidenced a significant increase in rest-activity rhythm amplitude and goodness of fit to the cosinor model. CONCLUSION: Light treatment alone did not improve nighttime sleep, daytime wake, or rest-activity rhythm. Light treatment plus melatonin increased daytime wake time and activity levels and strengthened the rest-activity rhythm. Future studies should resolve the question of whether these improvements can be attributed to melatonin or whether the two zeitgebers interact to amplify efficacy. [ABSTRACT FROM AUTHOR] |
| Copyright of Journal of the American Geriatrics Society is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: pbh DbLabel: Psychology and Behavioral Sciences Collection An: 105876321 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Dowling+GA%22">Dowling GA</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Burr+RL%22">Burr RL</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Van+Someren+EJW%22">Van Someren EJW</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hubbard+EM%22">Hubbard EM</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Luxenberg+JS%22">Luxenberg JS</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mastick+J%22">Mastick J</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cooper+BA%22">Cooper BA</searchLink> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Journal+of+the+American+Geriatrics+Society%22">Journal of the American Geriatrics Society</searchLink>. Feb2008, Vol. 56 Issue 2, p239-246. 8p. – Name: Abstract Label: Abstract Group: Ab Data: OBJECTIVES: To test whether the addition of melatonin to bright-light therapy enhances the efficacy in treating rest-activity (circadian) disruption in institutionalized patients with Alzheimer's disease (AD). DESIGN: Randomized, controlled trial. SETTING: Two nursing homes in San Francisco, California. PARTICIPANTS: Fifty subjects (mean age 86) with AD. INTERVENTION: Experimental subjects received 1 hour of morning light exposure (> or = 2,500 lux in gaze direction) Monday to Friday for 10 weeks and 5 mg melatonin (LM, n=16) or placebo (LP, n=17) in the evening. Control subjects (n=17) received usual indoor light (150-200 lux). MEASUREMENTS: Nighttime sleep variables, day sleep time, day activity, day:night sleep ratio, and rest-activity parameters were determined using actigraphy. RESULTS: Linear mixed models were employed to test the primary study hypotheses. No significant differences in nighttime sleep variables were found between groups. At the end of the intervention, the LM group showed significant improvement in daytime somnolence as indicated by a reduction in the duration of daytime sleep, an increase in daytime activity, and an improvement in day:night sleep ratio. The LM group also evidenced a significant increase in rest-activity rhythm amplitude and goodness of fit to the cosinor model. CONCLUSION: Light treatment alone did not improve nighttime sleep, daytime wake, or rest-activity rhythm. Light treatment plus melatonin increased daytime wake time and activity levels and strengthened the rest-activity rhythm. Future studies should resolve the question of whether these improvements can be attributed to melatonin or whether the two zeitgebers interact to amplify efficacy. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Journal of the American Geriatrics Society is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=105876321 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1111/j.1532-5415.2007.01543.x Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 8 StartPage: 239 Titles: – TitleFull: Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Dowling GA – PersonEntity: Name: NameFull: Burr RL – PersonEntity: Name: NameFull: Van Someren EJW – PersonEntity: Name: NameFull: Hubbard EM – PersonEntity: Name: NameFull: Luxenberg JS – PersonEntity: Name: NameFull: Mastick J – PersonEntity: Name: NameFull: Cooper BA IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 02 Text: Feb2008 Type: published Y: 2008 Identifiers: – Type: issn-print Value: 00028614 Numbering: – Type: volume Value: 56 – Type: issue Value: 2 Titles: – TitleFull: Journal of the American Geriatrics Society Type: main |
| ResultId | 1 |
